BTIG Reaffirms Buy Rating on Personalis, Increases Price Target to $12
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 11 2025
0mins
Should l Buy PSNL?
Source: Benzinga
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform is designed to help traders win in the markets every day with accurate stock market intelligence.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PSNL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PSNL
Wall Street analysts forecast PSNL stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 8.390
Low
10.00
Averages
11.17
High
12.00
Current: 8.390
Low
10.00
Averages
11.17
High
12.00
About PSNL
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Personalis Gains 10% After Medicare Coverage for NeXT Personal Test
- Medicare Coverage Expansion: Personalis announced that its NeXT Personal cancer recurrence test received Medicare coverage for specific lung cancer cases, which is expected to significantly enhance patient access to testing, particularly for one of the most common cancers in the US.
- Testing Technology Advantage: NeXT Personal is a molecular residual disease test designed to detect traces of circulating tumor DNA, allowing for earlier detection of tumors before standard imaging techniques, thereby improving patient treatment outcomes.
- Market Growth Catalyst: CEO Chris Hall stated that the decision for Medicare coverage will act as a catalyst for the company's continued growth, likely driving future revenue, especially among patients with non-small cell lung cancer.
- Financial Outlook: Personalis expects FY 2025 revenue to be between $69 million and $70 million, reflecting strong market demand and growth potential in the cancer testing sector.
See More
Personalis Secures Medicare Coverage, Stock Rises
- Medicare Coverage Milestone: Personalis's NeXT Personal molecular residual disease test has secured Medicare coverage, which is expected to significantly enhance patient access for lung cancer surveillance, thereby catalyzing the company's growth in the oncology market.
- Clinical Validation Support: The test has demonstrated high accuracy in identifying residual disease through clinical validation from the TRACERx collaboration, tracking up to 1,800 mutations, thus solidifying its role as a reliable tool for monitoring recurrence and residual disease.
- Market Performance Analysis: Although the stock is currently trading 16.6% and 13.7% below its 20-day and 50-day simple moving averages, it is 4.3% and 21.1% above its 100-day and 200-day averages, indicating a strong long-term trend with a 56.29% increase over the past 12 months.
- Analyst Outlook Positive: Analysts have assigned a consensus “Buy” rating with an average price target of $11.78, and Guggenheim recently raised its target to $13.00, reflecting strong market confidence in Personalis's future growth.
See More
Medicare Expands Coverage for NeXT Personal Lung Cancer Test
- Expanded Coverage: Personalis, Inc. announced that Medicare will reimburse its NeXT Personal molecular residual disease test for monitoring early to mid-stage non-small cell lung cancer patients, significantly broadening access beyond its previous breast cancer indication, thereby enhancing availability for Medicare beneficiaries.
- Importance of Lung Cancer Monitoring: Under the new determination, Medicare will cover NeXT Personal testing for Stage I to Stage III non-small cell lung cancer patients, as lung cancer remains the deadliest cancer in the U.S., with hundreds of thousands diagnosed annually and a high risk of recurrence following initial treatment.
- Technological Innovation: NeXT Personal utilizes whole-genome sequencing and advanced noise-suppression processes to identify tiny amounts of circulating tumor DNA in a patient's blood, tracking up to about 1,800 unique tumor mutations, allowing for earlier detection of residual or returning cancer compared to traditional imaging methods.
- Positive Market Reaction: Following the announcement, Personalis' stock traded over 16% higher in Tuesday's premarket, while retail sentiment on Stocktwits shifted from neutral to bullish, indicating strong market enthusiasm for the expanded coverage.
See More
Personalis Secures Medicare Coverage for Lung Cancer Monitoring
- Medicare Coverage Expansion: Personalis announced that its NeXT Personal molecular residual disease (MRD) test has secured Medicare coverage, aimed at enhancing monitoring for approximately 230,000 newly diagnosed lung cancer patients, thereby improving their treatment confidence and management capabilities.
- Clinical Validation Support: This coverage decision is grounded in clinical evidence generated through collaboration with TRACERx, demonstrating NeXT Personal's ability to accurately identify residual disease, further solidifying its clinical efficacy in lung cancer monitoring.
- Technological Advantage: NeXT Personal leverages whole-genome sequencing and advanced noise-suppression technology to track up to 1,800 mutations, providing a reliable tool for recurrence and residual disease monitoring, assisting clinicians in effective management where ctDNA detection is challenging.
- Market Growth Catalyst: CEO Chris Hall stated that this Medicare coverage not only broadens patient access to NeXT Personal but also serves as a catalyst for the company's continued growth, highlighting its strategic execution in the cancer management sector.
See More
AIGH Capital Fully Exits Lumen Technologies Stake
- Complete Exit: On February 2, 2026, AIGH Capital Management LLC reported a full exit from its Lumen Technologies stake, selling 2.55 million shares for an estimated $15.61 million, indicating potential concerns about Lumen's future amidst ongoing transformation challenges.
- Stock Performance: As of February 1, 2026, Lumen's stock was priced at $8.82, reflecting a 78.5% increase over the past year, significantly outperforming the S&P 500 by 64.2 percentage points, suggesting market optimism about its strategic pivot despite underlying debt issues.
- Strategic Business Shift: Following the $5.75 billion sale of its mass market fiber business to AT&T, Lumen aims to reinvest in new infrastructure, although the costly nature of this transformation raises questions about its long-term profitability and market positioning.
- Debt Burden Concerns: With over $17.6 billion in long-term debt reported in Q3 2025, Lumen faces significant financial challenges, and while the divestiture may alleviate some pressure, the company's ongoing transformation could complicate its recovery and stock performance outlook.
See More
Personalis Unveils New Study Highlighting MRD Assay Potential in Immunotherapy Monitoring
- Significant Findings: The study published by Personalis demonstrates that the NeXT Personal® assay possesses ultrasensitive molecular residual disease (MRD) detection capabilities, crucial for monitoring immunotherapy responses and improving patient survival rates.
- Early Response Identification: The research indicates that molecular responses can be detected a median of 23 days after initiating immunotherapy, with patients showing early responses experiencing significantly longer progression-free survival, underscoring the assay's clinical intervention importance.
- Lead Time Over Imaging: For patients whose disease progressed, NeXT Personal identified molecular progression a median of 161 days before imaging, highlighting its potential value in early intervention and possibly altering clinical decision-making.
- Survival Rate Enhancement: The study reveals that patients achieving molecular complete response had seven times higher overall survival compared to those who did not, emphasizing the critical role of ultrasensitive ctDNA testing in cancer treatment and potentially offering better therapeutic options for patients.
See More
Personalis Gains 10% After Medicare Coverage for NeXT Personal Test
- Medicare Coverage Expansion: Personalis announced that its NeXT Personal cancer recurrence test received Medicare coverage for specific lung cancer cases, which is expected to significantly enhance patient access to testing, particularly for one of the most common cancers in the US.
- Testing Technology Advantage: NeXT Personal is a molecular residual disease test designed to detect traces of circulating tumor DNA, allowing for earlier detection of tumors before standard imaging techniques, thereby improving patient treatment outcomes.
- Market Growth Catalyst: CEO Chris Hall stated that the decision for Medicare coverage will act as a catalyst for the company's continued growth, likely driving future revenue, especially among patients with non-small cell lung cancer.
- Financial Outlook: Personalis expects FY 2025 revenue to be between $69 million and $70 million, reflecting strong market demand and growth potential in the cancer testing sector.
See More
Personalis Secures Medicare Coverage, Stock Rises
- Medicare Coverage Milestone: Personalis's NeXT Personal molecular residual disease test has secured Medicare coverage, which is expected to significantly enhance patient access for lung cancer surveillance, thereby catalyzing the company's growth in the oncology market.
- Clinical Validation Support: The test has demonstrated high accuracy in identifying residual disease through clinical validation from the TRACERx collaboration, tracking up to 1,800 mutations, thus solidifying its role as a reliable tool for monitoring recurrence and residual disease.
- Market Performance Analysis: Although the stock is currently trading 16.6% and 13.7% below its 20-day and 50-day simple moving averages, it is 4.3% and 21.1% above its 100-day and 200-day averages, indicating a strong long-term trend with a 56.29% increase over the past 12 months.
- Analyst Outlook Positive: Analysts have assigned a consensus “Buy” rating with an average price target of $11.78, and Guggenheim recently raised its target to $13.00, reflecting strong market confidence in Personalis's future growth.
See More
Medicare Expands Coverage for NeXT Personal Lung Cancer Test
- Expanded Coverage: Personalis, Inc. announced that Medicare will reimburse its NeXT Personal molecular residual disease test for monitoring early to mid-stage non-small cell lung cancer patients, significantly broadening access beyond its previous breast cancer indication, thereby enhancing availability for Medicare beneficiaries.
- Importance of Lung Cancer Monitoring: Under the new determination, Medicare will cover NeXT Personal testing for Stage I to Stage III non-small cell lung cancer patients, as lung cancer remains the deadliest cancer in the U.S., with hundreds of thousands diagnosed annually and a high risk of recurrence following initial treatment.
- Technological Innovation: NeXT Personal utilizes whole-genome sequencing and advanced noise-suppression processes to identify tiny amounts of circulating tumor DNA in a patient's blood, tracking up to about 1,800 unique tumor mutations, allowing for earlier detection of residual or returning cancer compared to traditional imaging methods.
- Positive Market Reaction: Following the announcement, Personalis' stock traded over 16% higher in Tuesday's premarket, while retail sentiment on Stocktwits shifted from neutral to bullish, indicating strong market enthusiasm for the expanded coverage.
See More
Personalis Secures Medicare Coverage for Lung Cancer Monitoring
- Medicare Coverage Expansion: Personalis announced that its NeXT Personal molecular residual disease (MRD) test has secured Medicare coverage, aimed at enhancing monitoring for approximately 230,000 newly diagnosed lung cancer patients, thereby improving their treatment confidence and management capabilities.
- Clinical Validation Support: This coverage decision is grounded in clinical evidence generated through collaboration with TRACERx, demonstrating NeXT Personal's ability to accurately identify residual disease, further solidifying its clinical efficacy in lung cancer monitoring.
- Technological Advantage: NeXT Personal leverages whole-genome sequencing and advanced noise-suppression technology to track up to 1,800 mutations, providing a reliable tool for recurrence and residual disease monitoring, assisting clinicians in effective management where ctDNA detection is challenging.
- Market Growth Catalyst: CEO Chris Hall stated that this Medicare coverage not only broadens patient access to NeXT Personal but also serves as a catalyst for the company's continued growth, highlighting its strategic execution in the cancer management sector.
See More
AIGH Capital Fully Exits Lumen Technologies Stake
- Complete Exit: On February 2, 2026, AIGH Capital Management LLC reported a full exit from its Lumen Technologies stake, selling 2.55 million shares for an estimated $15.61 million, indicating potential concerns about Lumen's future amidst ongoing transformation challenges.
- Stock Performance: As of February 1, 2026, Lumen's stock was priced at $8.82, reflecting a 78.5% increase over the past year, significantly outperforming the S&P 500 by 64.2 percentage points, suggesting market optimism about its strategic pivot despite underlying debt issues.
- Strategic Business Shift: Following the $5.75 billion sale of its mass market fiber business to AT&T, Lumen aims to reinvest in new infrastructure, although the costly nature of this transformation raises questions about its long-term profitability and market positioning.
- Debt Burden Concerns: With over $17.6 billion in long-term debt reported in Q3 2025, Lumen faces significant financial challenges, and while the divestiture may alleviate some pressure, the company's ongoing transformation could complicate its recovery and stock performance outlook.
See More
Personalis Unveils New Study Highlighting MRD Assay Potential in Immunotherapy Monitoring
- Significant Findings: The study published by Personalis demonstrates that the NeXT Personal® assay possesses ultrasensitive molecular residual disease (MRD) detection capabilities, crucial for monitoring immunotherapy responses and improving patient survival rates.
- Early Response Identification: The research indicates that molecular responses can be detected a median of 23 days after initiating immunotherapy, with patients showing early responses experiencing significantly longer progression-free survival, underscoring the assay's clinical intervention importance.
- Lead Time Over Imaging: For patients whose disease progressed, NeXT Personal identified molecular progression a median of 161 days before imaging, highlighting its potential value in early intervention and possibly altering clinical decision-making.
- Survival Rate Enhancement: The study reveals that patients achieving molecular complete response had seven times higher overall survival compared to those who did not, emphasizing the critical role of ultrasensitive ctDNA testing in cancer treatment and potentially offering better therapeutic options for patients.
See More
